Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

2.33
-0.1200-4.90%
Post-market: 2.440.1126+4.83%19:59 EDT
Volume:1.70M
Turnover:4.07M
Market Cap:279.60M
PE:-2.21
High:2.51
Open:2.46
Low:2.32
Close:2.45
52wk High:3.23
52wk Low:0.9335
Shares:120.00M
Float Shares:104.94M
Volume Ratio:0.95
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0528
EPS(LYR):-1.1500
ROE:-60.75%
ROA:-26.22%
PB:1.82
PE(LYR):-2.03

Loading ...

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

GlobeNewswire
·
May 13

Fate Therapeutics says FT819 achieves low disease activity in SLE without chemotherapy conditioning

Reuters
·
May 11

Fate Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
May 08

Piper Sandler Remains a Buy on Fate Therapeutics (FATE)

TIPRANKS
·
May 06

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

GlobeNewswire
·
May 05

Fate Therapeutics posts Phase 1 FT819 lupus data showing B-cell remodeling without chemo conditioning

Reuters
·
May 04

Fate Therapeutics Announces Three Presentations at the 2026 Asgct Annual Meeting Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases

THOMSON REUTERS
·
May 04

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

GlobeNewswire
·
May 04

Fate Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 04

Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright

TIPRANKS
·
May 04

Fate Therapeutics grants 30,200 RSUs to newly hired employee under inducement plan

Reuters
·
May 02

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 02

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

GlobeNewswire
·
Apr 30

Fate Therapeutics announces annual shareholder meeting

Reuters
·
Apr 25

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting

GlobeNewswire
·
Apr 16

Fate Therapeutics to present at five investor conferences in second quarter 2026

Reuters
·
Apr 09

Fate Therapeutics grants 7,260 RSUs to newly hired employee under inducement plan

Reuters
·
Apr 03

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Fate Therapeutics Grants 50,700 RSU Inducement Awards to New Hires

Reuters
·
Mar 05

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 05